WallStreetZenWallStreetZen

NASDAQ: DBTX
Decibel Therapeutics Inc Stock

$3.25-0.04 (-1.22%)
Updated Feb 3, 2023
DBTX Price
$3.25
Fair Value Price
$4.72
Market Cap
$81.13M
52 Week Low
$1.61
52 Week High
$5.78
P/E
-1.37x
P/B
0.84x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$59.97M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.47
Operating Cash Flow
-$59M
Beta
0.89
Next Earnings
Mar 16, 2023
Ex-Dividend
N/A
Next Dividend
N/A

DBTX Overview

Decibel Therapeutics, Inc., a clinical-stage biotechnology company, engages in discovering and developing transformative treatments for hearing and balance disorders. Its product candidates and programs focuses on three areas, such as Gene Therapies for Congenital, Monogenic Hearing Loss designed to restore functional cells within the cochlea to address hearing disorders caused by single gene mutations; Gene Therapies for Hair Cell Regeneration designed to replace lost hair cells within the inner ear to address acquired hearing loss and balance disorders; and Otoprotection Therapeutic in clinical development to prevent hearing loss in cancer patients undergoing chemotherapy with cisplatin. The company's lead gene therapy product candidate is DB-OTO to provide hearing to individuals born with profound hearing loss due to mutation of the otoferlin gene. It is also developing DB-ATO and AAV.201, a gene therapy program designed to restore balance in patients with bilateral vestibulopathy by regenerating lost hair cells within the vestibule; DB-020 for the prevention of cisplatin-induced hearing loss, which is in Phase 1b clinical trial; AAV.103 to restore hearing in individuals with a gap junction beta-2 (GJB2) deficiency; AAV.104 to restore hearing in individuals with stereocilin (STRC) deficiency; and cochlear hair cell regeneration program, an AAV-based gene therapy that utilizes cell-selective expression of reprogramming factors to convert supporting cells into outer hair cells. Decibel Therapeutics, Inc. has a strategic collaboration with Regeneron Pharmaceuticals, Inc. to develop gene therapies for monogenic forms of congenital hearing loss. The company was formerly known as Hearing Inc. and changed its name to Decibel Therapeutics, Inc. in April 2014. Decibel Therapeutics, Inc. was incorporated in 2013 and is headquartered in Boston, Massachusetts.

Zen Score

Industry Average (28)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how DBTX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

DBTX ($3.25) is undervalued by 31.14% relative to our estimate of its Fair Value price of $4.72 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
DBTX ($3.25) is significantly undervalued by 31.14% relative to our estimate of its Fair Value price of $4.72 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
DBTX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more DBTX due diligence checks available for Premium users.

Be the first to know about important DBTX news, forecast changes, insider trades & much more!

DBTX News

Valuation

DBTX fair value

Fair Value of DBTX stock based on Discounted Cash Flow (DCF)
Price
$3.25
Fair Value
$4.72
Undervalued by
31.14%
DBTX ($3.25) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
DBTX ($3.25) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
DBTX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

DBTX price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-1.37x
Industry
10.7x
Market
15.09x

DBTX price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
0.84x
Industry
5.11x
DBTX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

DBTX's financial health

Profit margin

Revenue
$0.0
Net Income
-$16.0M
Profit Margin
0%
DBTX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials

Assets to liabilities

Assets
$142.3M
Liabilities
$45.5M
Debt to equity
0.47
DBTX's short-term assets ($126.29M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
DBTX's short-term assets ($126.29M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
DBTX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$13.7M
Investing
-$6.0M
Financing
-$54.0k
DBTX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

DBTX vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
DBTX$81.13M-1.22%-1.37x0.84x
ENLV$81.01M+0.92%-2.80x1.28x
ORMP$80.97M+0.49%-2.01x0.53x
MDWD$80.89M-0.79%-3.68x48.85x
CYBN$81.49M-4.35%-1.83x1.74x

Decibel Therapeutics Stock FAQ

What is Decibel Therapeutics's quote symbol?

NASDAQ: DBTX) Decibel Therapeutics trades on the NASDAQ under the ticker symbol DBTX. Decibel Therapeutics stock quotes can also be displayed as NASDAQ: DBTX.

If you're new to stock investing, here's how to buy Decibel Therapeutics stock.

What is the 52 week high and low for Decibel Therapeutics (NASDAQ: DBTX)?

(NASDAQ: DBTX) Decibel Therapeutics's 52-week high was $5.78, and its 52-week low was $1.61. It is currently -43.77% from its 52-week high and 101.86% from its 52-week low.

How much is Decibel Therapeutics stock worth today?

(NASDAQ: DBTX) Decibel Therapeutics currently has 24,964,502 outstanding shares. With Decibel Therapeutics stock trading at $3.25 per share, the total value of Decibel Therapeutics stock (market capitalization) is $81.13M.

Decibel Therapeutics stock was originally listed at a price of $18.10 in Feb 16, 2021. If you had invested in Decibel Therapeutics stock at $18.10, your return over the last 1 years would have been -82.04%, for an annualized return of -82.04% (not including any dividends or dividend reinvestments).

How much is Decibel Therapeutics's stock price per share?

(NASDAQ: DBTX) Decibel Therapeutics stock price per share is $3.25 today (as of Feb 3, 2023).

What is Decibel Therapeutics's Market Cap?

(NASDAQ: DBTX) Decibel Therapeutics's market cap is $81.13M, as of Feb 6, 2023.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Decibel Therapeutics's market cap is calculated by multiplying DBTX's current stock price of $3.25 by DBTX's total outstanding shares of 24,964,502.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.